LUNAC Therapeutics Overview
- Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$5.91M
- Investors
-
8
LUNAC Therapeutics General Information
Description
Developer of advanced oral anticoagulant drugs designed to treat and prevent life-threatening thrombotic events. The company's drugs help to minimize the bleeding risk in patients, enabling healthcare providers to handle high-risk patients with safe dose escalation.
Contact Information
Website
www.lunactherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Nexus, Discovery Way
- Yorks
- Leeds LS2 3AA
- England, United Kingdom
LUNAC Therapeutics Timeline
LUNAC Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC | 13-May-2021 | $5.91M | 000.00 | Completed | Startup | |
| 5. Grant | 01-Jun-2020 | 00000 | 0000 | Completed | Startup | |
| 4. Early Stage VC | 06-May-2020 | 00.000 | 0000 | 0000 | Completed | Startup |
| 3. Grant | 02-Dec-2019 | 00.000 | 00.000 | Completed | Startup | |
| 2. Early Stage VC (Series A) | 14-Nov-2019 | $7.06M | $7.06M | 000.00 | Completed | Startup |
| 1. Grant | 01-Sep-2019 | $1.96M | Completed | Startup |
LUNAC Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
LUNAC Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of advanced oral anticoagulant drugs designed to treat and prevent life-threatening thrombotic events. The com
Drug Discovery
Leeds, United Kingdom
000.00
0000000000 0
000.00
00000
ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000 000000000
Leiden, Netherlands
00
As of 0000
000.00
000000000000
000.00
000000
uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000 000000000
Rockville, MD
00
As of 0000
0000
0000
0000-00-00
00000000000
0000
Add Comparison
LUNAC Therapeutics Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| VarmX | Venture Capital-Backed | Leiden, Netherlands | 00 | 000.00 | 000000000000 | 000.00 |
| 000000000 00000000 | Venture Capital-Backed | Rockville, MD | 00 | 0000 | 00000000000 | 0000 |
LUNAC Therapeutics Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Julian Howell MD | Co-Chief Executive Officer | ||
| Helen Philippou | Scientific Co-Founder & Board Member | ||
| Richard Foster | Scientific Co-Founder | ||
| Richard Brooks | Head of Finance |
LUNAC Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Helen Philippou | LUNAC Therapeutics | Scientific Co-Founder & Board Member | 000 0000 |
| Mary Canning Ph.D | Epidarex Capital | Board Member | 000 0000 |
| Mervyn Turner Ph.D | Self | Chairman | 000 0000 |
| Peter Finan Ph.D | Epidarex Capital | Board Member | 000 0000 |
| Sarah Jarmin | LUNAC Therapeutics | Board Member | 000 0000 |
LUNAC Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Future Fund | Government | Minority | 000 0000 | 000000 0 | |
| Mercia Asset Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Northern Powerhouse Investment Fund | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
| UK Government's Biomedical Catalyst funding | Government | 000 0000 | 000000 0 | ||
| Caribou Property Ltd | Corporation | Minority | 000 0000 | 000000 0 |